Nelson Espinell Gonzalez, MD
Interventional Cardiology · Manati, PRNPI 1093966079
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Medtronic at 41.8% of the total. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.
Across 500 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$911
- Abbott$685
- AstraZeneca$275
- Teleflex LLC$230
- plus $624 from 8 others
What the payments were for
- Travel & lodging$5556%
- Food & beverage$8,22593%
- Gifts$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 156 | $3,703 |
| Boston Scientific | 204 | $2,426 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $911 |
| Abbott | 70 | $685 |
| AstraZeneca | 13 | $275 |
| Teleflex LLC | 3 | $230 |
| Chiesi USA, Inc. | 5 | $144 |
| Biotronik Inc. | 2 | $124 |
| Boehringer Ingelheim | 4 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Terumo Medical Corporation | 1 | $67 |
| Cordis US CORP. | 3 | $47 |
| Johnson & Johnson | 1 | $23 |
| Inari Medical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$687
- ONYX FRONTIER$332
- Resolute$232
- CLARIA MRI QUAD CRT-D SURESCAN$121
- General - CT_IC$120
- ARCTIC FRONT ADVANCE$116
- Micra$115
- Amplia MRI$115
- Watchman$113
- Xience Sierra Coronary Stent System$102
- LifeVest$100
How this compares
$8,855 in reported general payments places this provider in the 40th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 65 | $33,539 |
| EliquisApixaban | 33 | $26,216 |
| FarxigaDapagliflozin Propanediol | 34 | $22,347 |
| JardianceEmpagliflozin | 13 | $11,656 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 29 | $4,301 |
| Metoprolol Succinate | 144 | $2,250 |
| Losartan Potassium | 226 | $2,152 |
| Atorvastatin Calcium | 173 | $1,883 |
| ClopidogrelClopidogrel Bisulfate | 170 | $1,631 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 90 | $1,550 |
| Candesartan Cilexetil | 14 | $1,248 |
| Hydralazine Hcl | 81 | $1,089 |
| Carvedilol | 143 | $1,054 |
| Amlodipine Besylate | 228 | $1,021 |
| Rosuvastatin Calcium | 54 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $275 | $55,88599 claims |
| Boehringer IngelheimJardiance | $100 | $11,65613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Manati
- Ricardo SantiagoManati$131K
- Julio Valentin NievesManati$32K
- Valentin del Rio SantiagoManati$28K
- Abner Nieves TorresManati$8K
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Alejandro Lopez MasPonce$142K
- Edwin I Perez MarreroSan Juan$129K
- Pedro Colon HernandezCaguas$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.